Last year, pharmaceutical giant AbbVie (NYSE: ABBV) lost patent exclusivity for its biggest cash cow, immunology medicine ...

NORTH CHICAGO, IL, USA I 18, 2024 I AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® ...

Allergan Aesthetics, an AbbVie company, launched AMI Business Education, a new addition to the AMI Online learning platform available for free to all Allergan Aesthetics customers. This innovative ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of AbbVie (NYSE:ABBV) with a Outperform ...

Pre-tax profits at AbbVie’s global production facility for Botox, in Westport, last year declined by 27pc to $1.1bn (€1.04bn) ...

Presbyopia is an age-related refractive condition marked by a gradual decline in near vision, typically emerging between ages ...

Allergan first set up on a greenfield site outside Westport 47 years ago and it has provided a bonanza to the Co Mayo town.

AbbVie Migraine Career Catalyst Awardtm contest winners shared inspiring stories and professional goals, showcasing their triumphs over the challenges of living with migraine AbbVie, a leader in ...

Akamine joins Kailera from Cerevel Therapeutics where he served as chief legal officer and corporate secretary until the ...

Other key growth drivers for AbbVie came from its business development deals. For example, the company's acquisition of Allergan in 2020 added products including migraine therapies Qulipta and Ubrelvy ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.